No Data
No Data
Zhejiang Garden Biopharmaceutical (300401.SZ): The designed annual production capacity of the fodder-grade Vitamin D3 product of the company is 3600 tons.
Zhejiang Garden Biopharmaceutical (300401.SZ) stated on the investor interaction platform on June 27 that the design capacity of the company's fodder grade VD3 product is 3,600 tons per year. The core competitiveness of the company's vitamins sector mainly includes: a clear industry chain, leading production technology, lower production costs, prominent business scale and good market channel construction.
Why Investors Shouldn't Be Surprised By Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) 31% Share Price Surge
Zhejiang Garden Biopharmaceutical Co.,Ltd. (SZSE:300401) shares have continued their recent momentum with a 31% gain in the last month alone. The last 30 days bring the annual gain to a very sharp
Zhejiang Garden Biopharmaceutical (300401.SZ): Subsidiary Luo Hongming Pian was granted a pharmaceutical registration certificate.
On June 25th, Gelunhui reported that Zhejiang Garden Biopharmaceuticals (300401.SZ) announced that its wholly-owned subsidiary, Zhejiang Garden Pharmaceutical Co., Ltd. (hereinafter referred to as "Garden Pharmaceutical "), recently received the Drug Registration Certificate of "Roxithromycin Tablets" approved and issued by the National Medical Products Administration. Roxithromycin tablets are mainly used to treat infections caused by roxithromycin-sensitive pathogens. Roxithromycin tablets are a type B variety in the "National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug List (2023)."
Individual Investors Among Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 6.6% Last Week
Key Insights The considerable ownership by individual investors in Zhejiang Garden BiopharmaceuticalLtd indicates that they collectively have a greater say in management and business strategy The to
Garden Biology (300401.SZ): In the future, we will unswervingly promote the dual layout of “chemical synthesis and biosynthesis”
Gelonghui, May 9, 丨 Garden Biology (300401.SZ) said on the investor interactive platform that the company's existing products mainly use chemical synthesis. In the future, the company will unswervingly promote the dual layout of “chemical synthesis and biosynthesis”. Currently, it has invested abroad to establish a joint venture “Zhejiang Garden Biotechnology Co., Ltd.” to increase the company's market and technology development efforts in the field of amino acid and vitamin biosynthesis. At the same time, the company plans to invest in the construction of a “pilot base project with an annual output of 10,000 tons of L-alanine (fermentation method) and biological manufacturing”, which uses advanced biological manufacturing methods.
Garden Biotech (300401.SZ) 2023 equity distribution: $0.71 for every 10 shares, shares registered on May 14
According to the Zhitong Finance App, Huayuan Biotech (300401.SZ) announced that the company's 2023 equity distribution plan is to distribute a cash dividend of 0.71 yuan to all shareholders for every 10 shares based on the total share capital on the registration date of the company's equity distribution. The share registration date for this equity distribution is: May 14, 2024, and the excluding dividend date is: May 15, 2024.
No Data